← Back to Search

NA

Participants with Suspected Lung Cancer for Non-Small Cell Lung Cancer

Phase < 1
Waitlist Available
Research Sponsored by Janssen Research & Development, LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to week 6
Awards & highlights

Study Summary

This study is evaluating whether there are spontaneous changes in pathological response in the surgically resected tumor (Non-small cell lung cancer [NSCLC]).

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to week 6
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to week 6 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Percent of Residual Viable Tumor Cells (% RVT) at the Time of Non-small Cell Lung Cancer (NSCLC) Resection
Secondary outcome measures
T-cell Receptor (TCR) Repertoire Sequencing in Tumor
Tissue Frequencies of Immune Cell Subsets Determined via Semi-quantitative Immunofluorescence and/or Imaging Mass Cytometry
Tumor Gene Expression Analysis by Ribonucleic Acid (RNA)-sequencing or Polymerase Chain Reaction (PCR) Techniques
+1 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Participants with Suspected Lung CancerExperimental Treatment2 Interventions
Eligible participants with suspected lung cancer will be enrolled and undergo diagnostic and research bronchoscopic biopsies and research blood sample collection for biomarker analysis. Those participants who proceed to surgical resection will have additional research samples taken from the resected tumor and additional research blood samples drawn for biomarker analyses at the resection visit and at the post-operative follow up visit. Participants will then be followed clinically for two years for evidence of recurrence or until participants with confirmed lung cancer recurrence, whichever occurs earlier.

Find a Location

Who is running the clinical trial?

Janssen Research & Development, LLCLead Sponsor
975 Previous Clinical Trials
6,384,327 Total Patients Enrolled
Janssen Research & Development, LLC Clinical TrialStudy DirectorJanssen Research & Development, LLC
745 Previous Clinical Trials
3,959,924 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
A Study to Examine Biomarkers From Lung and Blood Samples in Participants With Suspected Lung Cancer
2022. "A Study to Examine Biomarkers From Lung and Blood Samples in Participants With Suspected Lung Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04951154.
~11 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top